NCT06685068View on ClinicalTrials.gov

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

May 29, 2028

Study Completion Date

June 29, 2028

Conditions
Advanced Solid Tumor
Interventions
DRUG

GEN1286

Specified dose on specified days

Trial Locations (4)

49546

RECRUITING

START Midwest, Grand Rapids

78229

RECRUITING

START San Antonio, San Antonio

84119

RECRUITING

START Mountain Region, West Valley City

02114

RECRUITING

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Genmab
All Listed Sponsors
lead

Genmab

INDUSTRY

NCT06685068 - A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter